Research and Clinical Trials
Search Cancer Clinical Trials
Clinical Trials
New Search
| Title | A Study in Second Line Metastatic Colorectal Cancer |
|---|---|
| Disease/Condition | Colorectal Cancer |
| Description | The purpose of this study is to compare overall survival in patients with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI. |
| Eligibility Criteria | To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patients must be 18 Years and older * Subjects must have histologically or cytologically confirmed metastatic colorectal cancer (patients are eligible to enroll irrespective of KRAS mutation status). * The patient has received first-line combination therapy of bevacizumab, oxaliplatin, and a fluoropyrimidine for metastatic disease and: * Experienced radiographic disease progression during first-line therapy, OR * Experienced radiographic disease progression within 6 months after the last dose of first-line therapy, OR * Discontinued part or all of first-line therapy due to toxicity and experienced radiographic disease progression within 6 months after the last dose of first-line therapy. |
| Principal Investigator | Sanjay Goel, MD |
| Phone | (718) 405-2488 |
| Contact Email | sgoel@montefiore.org |
| Post Date | 08/04/2010 |
| Protocol Number | 10-12-384/West |
| Status | Recruiting |
| Current Trial Type | Interventional |
